EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Impact of FDA’s HCT/P ZIKV Recommendations on Cord Blood Unit Eligibility and Utilization in a Large Public Cord Blood Bank

Dana S Guggenheim, Joanne Kurtzberg iD, Beth H Shaz iD

Stem Cells Translational Medicine · 2024

DOI: 10.1093/stcltm/szae008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Stem Cells Translational Medicine, 2024. Verfasst von Dana S Guggenheim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Duke University, Durham, NC. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Zika Virus Infection, Fetal Blood, Blood Banks. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cord blood units (CBUs) that are ineligible for licensure due to incomplete compliance with FDA recommendations may be used for hematopoietic stem cell transplantation under urgent medical need and an Investigational Drug Application. The largest reason for CBU donor ineligibility is Zika virus (ZIKV) risk. The study’s objective was to analyze the impact of current FDA recommendations for ZIKA risk on a large public cord blood bank and propose updated recommendations.

Methods

We performed a retrospective analysis of Carolinas Cord Blood Bank (CCBB), an FDA licensed public CBB, using data from January 1, 2016 to November 21, 2023 and compared FDA recommendations for transfusion transmitted infections (TTI) for blood products and relevant communicable disease agents or diseases for human cell, tissue, or cellular or tissue-based products (HCT/Ps).

Results

CCBB: 9057 (84.3% licensed) CBUs were banked. 984/1682 (58.5%) of unlicensed CBUs had ZIKV risk. 22.0% of CBUs with ZIKV risk were from Hispanic parents, compared to 16.1% of all units. 31 of IND CBUs (11 due to ZIKV risk without reported ZIKV transmission) were safely infused. FDA Guidance: HCT/P ZIKV, HIV, and vCJD recommendations have not been updated since 2018 in contrast to FDA removal of ZIKV as a relevant TTI in 2021 and updating HIV and vCJD guidance related to TTI in 2023 and 2022, respectively.

Discussion

The FDA should consider new data to revise the HCT/P donor eligibility recommendations, which will increase the number of eligible HCT/P donors, and potentially improve access to therapies for a more diverse patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

United States Food and Drug AdministrationZika Virus InfectionFetal BloodBlood BanksHumansUnited StatesZika VirusRetrospective StudiesFemaleMale

Stichwörter der Autor:innen

Cord BloodHCT/PsPublic policyZika Virus

Autor:innen und Institutionen

  • Duke University, Durham, NC.

ORCID-Profile: Joanne Kurtzberg, Beth H Shaz

Zitieren

APA

Guggenheim, D. S., Kurtzberg, J., & Shaz, B. H. (2024). Impact of FDA’s HCT/P ZIKV Recommendations on Cord Blood Unit Eligibility and Utilization in a Large Public Cord Blood Bank. Stem Cells Translational Medicine. https://doi.org/10.1093/stcltm/szae008

Vancouver

Guggenheim DS, Kurtzberg J, Shaz BH. Impact of FDA’s HCT/P ZIKV Recommendations on Cord Blood Unit Eligibility and Utilization in a Large Public Cord Blood Bank. Stem Cells Translational Medicine. 2024. doi:10.1093/stcltm/szae008

BibTeX
@article{Guggenheim2024,
  author = {Guggenheim, Dana S and Kurtzberg, Joanne and Shaz, Beth H},
  title = {Impact of FDA’s HCT/P ZIKV Recommendations on Cord Blood Unit Eligibility and Utilization in a Large Public Cord Blood Bank},
  journal = {Stem Cells Translational Medicine},
  year = {2024},
  doi = {10.1093/stcltm/szae008}
}
Kostenlos starten →